Table 3.
Mixed Modeling of Weekly Change in Major Symptom Burden Among Three Groups During and After CXRT (785 Observations)a
| Effect | Est | SE | Pr > |t| |
|---|---|---|---|
| Systemic symptoms (fatigue, lack of appetite, disturbed sleep, drowsiness) | |||
| Weeks 0–7 | |||
| IMRT vs. PBT | 0.12 | 0.13 | 0.338 |
| 3DCRT vs. PBT | 0.10 | 0.12 | 0.394 |
| IMRT vs. 3DCRT | –0.02 | 0.12 | 0.840 |
| 3DCRT/IMRT vs. PBT | 0.11 | 0.11 | 0.307 |
| Weeks 7–12 | |||
| IMRT vs. PBT | –0.35 | 0.16 | 0.026 |
| 3DCRT vs. PBT | –0.31 | 0.15 | 0.032 |
| IMRT vs. 3DCRT | 0.04 | 0.13 | 0.775 |
| 3DCRT/IMRT vs. PBT | –0.33 | 0.14 | 0.016 |
| Total radiation dose (Gy) | –0.10 | 0.04 | 0.007 |
| Pain | |||
| Weeks 0–7 | |||
| IMRT vs. PBT | 0.24 | 0.10 | 0.014 |
| 3DCRT vs. PBT | 0.17 | 0.11 | 0.118 |
| IMRT vs. 3DCRT | 0.08 | 0.09 | 0.409 |
| 3DCRT/IMRT vs. PBT | 0.21 | 0.09 | 0.019 |
| Weeks 7–12 | |||
| 3DCRT vs. PBT | –0.38 | 0.21 | 0.070 |
| IMRT vs. PBT | –0.51 | 0.20 | 0.010 |
| IMRT vs. 3DCRT | –0.13 | 0.17 | 0.452 |
| 3DCRT/IMRT vs. PBT | –0.46 | 0.19 | 0.013 |
| Total radiation dose (Gy) | –0.09 | 0.04 | 0.027 |
3DCRT = three-dimensional conformal radiation therapy; CXRT = concurrent chemoradiation therapy; Est = estimate of the effect of independent variables (or factors) on symptoms; IMRT = intensity-modulated radiotherapy; PBT = proton-beam therapy; SE = standard error.
a
Age, sex, race, cancer stage, Eastern Cooperative Oncology Group performance status, body mass index, total radiation dose, previous chemotherapy, and previous surgery were included in all models.